DelveInsight’s in-depth analysis highlights strong growth prospects for the PI3K inhibitors market across the 7MM through 2034. Leading companies such as Roche/Genentech (ITOVEBI), Novartis (PIQRAY), Gilead Sciences (ZYDELIG), Kazia Therapeutics (Paxalisib), and Celcuity (Gedatolisib) are driving this expansion, fueled by the increasing use of PI3K inhibitors in both hematological and...